. 1991 Dec;14(2):147-55; discussion 155-6.
Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey
Affiliations
- PMID: 1812429
Item in Clipboard
Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey
NIPH Ann.
1991 Dec.
Abstract
Results from the serum bactericidal assay (BA) after immunization of human volunteers with the Norwegian serogroup B meningococcal outer membrane vesicle vaccine are surveyed. In the phase II trials with adults we found very high seroconversion rates (greater than 98%) against the vaccine strain in the BA. Details in the antigenic composition of the inoculum used in the BA seem very important as shown here by finding lower bactericidal titres with teenager sera when tested with a variant of the standard inoculum. The present preliminary report corresponds to the presentation given at the Report Meeting on the Norwegian Meningococcal Vaccine Trial, Oslo, 12 September, 1991.
Similar articles
-
Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies.NIPH Ann. 1991 Dec;14(2):169-79; discussion 180-1. NIPH Ann. 1991. PMID: 1687481
-
Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial.NIPH Ann. 1991 Dec;14(2):183-4; discussion 185-6. NIPH Ann. 1991. PMID: 1812431 Clinical Trial. No abstract available.
-
Design of clinical trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.NIPH Ann. 1991 Dec;14(2):81-91; discussion 91-3. NIPH Ann. 1991. PMID: 1812439
-
Serologic correlates of protection for evaluating the response to meningococcal vaccines.Expert Rev Vaccines. 2004 Feb;3(1):77-87. doi: 10.1586/14760584.3.1.77. Expert Rev Vaccines. 2004. PMID: 14761245 Review.
-
The status of vaccines to meningococcal and gonococcal disease.Ann Inst Pasteur Microbiol (1985). 1985 Nov-Dec;136B(3):341-55. doi: 10.1016/s0769-2609(85)80079-x. Ann Inst Pasteur Microbiol (1985). 1985. PMID: 2870677 Review.
Cited by
-
Prospects for vaccine prevention of meningococcal infection.Clin Microbiol Rev. 2006 Jan;19(1):142-64. doi: 10.1128/CMR.19.1.142-164.2006. Clin Microbiol Rev. 2006. PMID: 16418528 Free PMC article. Review.
-
Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis.J Clin Microbiol. 2000 Aug;38(8):2878-84. doi: 10.1128/JCM.38.8.2878-2884.2000. J Clin Microbiol. 2000. PMID: 10921943 Free PMC article.
-
Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.Clin Diagn Lab Immunol. 2005 May;12(5):599-605. doi: 10.1128/CDLI.12.5.599-605.2005. Clin Diagn Lab Immunol. 2005. PMID: 15879021 Free PMC article.
-
Importance of complement source in measuring meningococcal bactericidal titers.Clin Diagn Lab Immunol. 2001 May;8(3):616-23. doi: 10.1128/CDLI.8.3.616-623.2001. Clin Diagn Lab Immunol. 2001. PMID: 11329468 Free PMC article. Clinical Trial.
-
Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.Infect Immun. 1995 Dec;63(12):4642-52. doi: 10.1128/iai.63.12.4642-4652.1995. Infect Immun. 1995. PMID: 7591118 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources